ClinicalTrials.gg
CompletedNCT01241760Updated Jun 4, 2014Results posted

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

A Phase 3 interventional study of Ribavirin and Telaprevir in Genotype 1 Chronic Hepatitis C and Treatment Naive, sponsored by Janssen Infectious Diseases BVBA. Completed at 102 sites in 13 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-06-04.

Sponsored by Janssen Infectious Diseases BVBA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
744
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.

Enrollment
8th of 174
744 · median 78
Started
2010
with 6 others
Phase 3
56 of 174
none open now
Registered
81st of 174
by date

Among the 174 studies testing ribavirin in Hepatitis C, this one is the 8th largest by enrollment, is one of 7 that started in 2010, is one of 56 in phase 3, and was the 81st registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 174 studies testing ribavirin in Hepatitis C as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of telaprevir administered twice daily versus every 8 hours in combination with Peg-IFN-alfa-2a and ribavirin in treatment-naïve participants with chronic HCV genotype 1 infection.

Read the detailed description

This is a randomized (study drug assigned by chance), open-label (all persons know the study drug assignment) multicenter study to evaluate the effectiveness of telaprevir administered orally as 1125 milligram (mg) twice daily versus 750mg every 8 hours in combination with Peg-IFN-alfa-2a, administered via intramuscular injection once a week, and ribavirin, administered as an oral tablet twice a day, in treatment-naïve study participants with chronic hepatitis C virus (HCV) genotype 1 infection.

Telaprevir will be given orally (by mouth) from Day 1 through Week 12 as 3 tablets (1125mg) twice daily or 2 tablets (750mg) every 8 hours. Peg-IFN-alfa-2a will be administered once a week as an injection under the skin (180 microgram/week) from Day 1 through Week 24 or 48 (based on the patient's treatment response on week 4). Ribavirin is administered orally (by mouth) twice daily from Day 1 through Week 24 or 48 (based on the participant's treatment response on week 4) as 1,000-1,200 mg per day. After the end of treatment (Week 24, Week 48, or at early discontinuation of all study drugs), participants with undetectable HCV RNA at end of treatment will be required to attend follow-up visits until Week 72 safety/tolerability assessments will be performed throughout the treatment period and during the follow-up period.

03

Conditions studied

  • Genotype 1 Chronic Hepatitis C
  • Treatment Naive

Browse trials for

Keywords

  • Genotype 1 chronic hepatitis C
  • VX-950-C211
  • VX-950
  • IL28B
  • Telaprevir
  • Hepatitis C
  • BID
  • Q8h
  • SOC
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has chronic infection genotype 1 with HCV RNA level > 1,000 IU/mL
  • Patients should not have had any previous treatment for hepatitis C
  • Patient must have documentation of a liver within 2 years before the screening visit or the patient must agree to have a biopsy performed within the screening period
  • Patients with cirrhosis should have serum alpha-fetoprotein (AFP) \<= 50 ng/mL. If AFP > 50 ng/mL, absence of a mass must be demonstrated by ultrasound within the screening period
  • A female patient of and a nonvasectomized male patient who has a female partner of childbearing potential must agree to the use of 2 effective methods of from screening until 6 months (female patient) or 7 months (male patient) after the last dose of RBV.

Exclusion criteria

Exclusion Criteria:

  • Patient is infected or co-infected with of another genotype than genotype 1 and/or patient is infected with more than one genotype subtype
  • Patient has a pre-existing psychiatric condition
  • Patient has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis C
  • Patient has (HIV) or virus (HBV) co-infection
  • Patient has active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
744 participants (actual)

Study arms

  • Experimental
    001 T(q8h) / PR

    Telaprevir (T) 750 mg (2 oral tablets) every 8 hours for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)

    Drug: Ribavirin · Drug: Pegylated interferon alfa-2a · Drug: Telaprevir

  • Experimental
    002 T(b.i.d.) / PR

    Telaprevir (T) 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)

    Drug: Ribavirin · Drug: Telaprevir · Drug: Pegylated interferon alfa-2a

Interventions

  • Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4

  • 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks

  • 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4

  • 750 mg (2 oral tablets) every 8 hours for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)

    The table below shows the percentage of participants achieving Sustained Virologic Response 12 weeks after last planned dose of study medication (SVR12 planned). SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL).

    Time frame: End of trial, 12 weeks after last planned dose

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)

    The table below shows the percentage of participants achieving SVR 24 weeks after the last planned dose of study medication. SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL). The response for T12(b.i.d)/PR group is higher than that after 12 weeks because HCV RNA data for two participants were missing for SVR assessment at that time. Consequently, by definition of SVR12, they were counted as not having achieved SVR12.

    Time frame: End of trial, 24 weeks after last planned dose

  2. Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)

    The table below shows the percentage of participants achieving SVR 72 weeks after the start of study medication (SVR72 planned). SVR was defined as having plasma Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 IU/mL, target not detected, at end of treatment and up to 72 weeks after start of study medication (i.e., no confirmed detectable HCV RNA in between).

    Time frame: End of trial, 72 weeks after the start of study medication

  3. Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.

    The table below shows the percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels, which means less than 25 IU/ml, target not detected, at different time points during the study.

    Time frame: Baseline, Week 4 and Week 4+12.

  4. Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs

    The table below shows the percentage of participants who met a stopping rule, defined as having a hepatitis C virus (HCV) ribonucleic acid (RNA) value at Week 4 \>1000 IU/mL and at Weeks 12, 24, 32 and 40 ≥25 IU/mL.

    Time frame: Week 4, 12, 24, 32, 40

  5. Percentage of Participants Who Relapsed During Follow-up Period

    The table below shows the percentage of participants who relapsed (ie, those having confirmed detectable hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] during the 12-week follow-up period after previous HCV RNA \<25 IU/mL, target not detected, at end of treatment).

    Time frame: During Follow-Up (24 weeks after the last dose of study drug)

  6. Percentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)

    The table below shows the effect of interleukin 28B (IL28B) gene's subtype (CC, CT or TT genotype) on the primary outcome measure: SVR12 planned.

    Time frame: End of trial, 12 weeks after the last planned dose

07

Results

Posted Jun 4, 2014

Participant flow

This study evaluated the effectiveness of telaprevir administered twice daily versus every 8 hours in combination with pegylated interferon and ribavirin in treatment-naïve participants with chronic HCV genotype 1 infection.

Participant flow — Overall Study
MilestoneT12(q8h)/PRT12(b.i.d.)/PR
Started371369
Completed337329
Not completed3440
Withdrew: Adverse event10
Withdrew: Lost to follow-up1822
Withdrew: Withdrawal by subject1313
Withdrew: Switch to commercially available medicat14
Withdrew: Other11

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)

The table below shows the percentage of participants achieving Sustained Virologic Response 12 weeks after last planned dose of study medication (SVR12 planned). SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL).

Time frame:
End of trial, 12 weeks after last planned dose
Reported as:
Number · percentage of participants with response
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)
percentage of participants with responseT12(q8h)/PRT12(b.i.d.)/PR
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)72.874.3
Statistical analysis
  • T12(q8h)/PR vs T12(b.i.d.)/PR · Regression, Logistic · Difference in proportion of response, %: 1.5 · 95% CI -4.9 to 12Observed data
SecondaryPercentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)

The table below shows the percentage of participants achieving SVR 24 weeks after the last planned dose of study medication. SVR was defined as having Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 international units/milliliter (IU/mL). The response for T12(b.i.d)/PR group is higher than that after 12 weeks because HCV RNA data for two participants were missing for SVR assessment at that time. Consequently, by definition of SVR12, they were counted as not having achieved SVR12.

Time frame:
End of trial, 24 weeks after last planned dose
Reported as:
Number · percentage of participants with response
Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)
percentage of participants with responseT12(q8h)/PRT12(b.i.d.)/PR
Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)72.874.8
SecondaryPercentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)

The table below shows the percentage of participants achieving SVR 72 weeks after the start of study medication (SVR72 planned). SVR was defined as having plasma Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels less than 25 IU/mL, target not detected, at end of treatment and up to 72 weeks after start of study medication (i.e., no confirmed detectable HCV RNA in between).

Time frame:
End of trial, 72 weeks after the start of study medication
Reported as:
Number · percentage of participants with response
Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)
percentage of participants with responseT12(q8h)/PRT12(b.i.d.)/PR
Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)69.070.2
SecondaryPercentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.

The table below shows the percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels, which means less than 25 IU/ml, target not detected, at different time points during the study.

Time frame:
Baseline, Week 4 and Week 4+12.
Reported as:
Number · percentage of participants with response
Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.
percentage of participants with responseT12(q8h)/PRT12(b.i.d.)/PR
Baseline00
at Week 467.469.4
at Week 4 and Week 1263.166.1
SecondaryPercentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs

The table below shows the percentage of participants who met a stopping rule, defined as having a hepatitis C virus (HCV) ribonucleic acid (RNA) value at Week 4 \>1000 IU/mL and at Weeks 12, 24, 32 and 40 ≥25 IU/mL.

Time frame:
Week 4, 12, 24, 32, 40
Reported as:
Number · percentage of participants
Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs
percentage of participantsT12(q8h)/PRT12(b.i.d.)/PR
Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs9.710.3
SecondaryPercentage of Participants Who Relapsed During Follow-up Period

The table below shows the percentage of participants who relapsed (ie, those having confirmed detectable hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] during the 12-week follow-up period after previous HCV RNA \<25 IU/mL, target not detected, at end of treatment).

Time frame:
During Follow-Up (24 weeks after the last dose of study drug)
Reported as:
Number · percentage of participants
Percentage of Participants Who Relapsed During Follow-up Period
percentage of participantsT12(q8h)/PRT12(b.i.d.)/PR
Percentage of Participants Who Relapsed During Follow-up Period7.27.7
SecondaryPercentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)

The table below shows the effect of interleukin 28B (IL28B) gene's subtype (CC, CT or TT genotype) on the primary outcome measure: SVR12 planned.

Time frame:
End of trial, 12 weeks after the last planned dose
Reported as:
Number · percentage of participants with response
Percentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)
percentage of participants with responseT12(q8h)/PRT12(b.i.d.)/PR
CC genotype (n = 108; n = 103)86.892.4
CT genotype (n = 207; n = 207)67.867.5
TT genotype (n = 56; n = 59)64.965.5

Adverse events

Collected over Adverse event data were collected for the duration of study (12 weeks after the last dose).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T12(q8h)/PR—35/371 (9.4%)359/371 (96.8%)
T12(b.i.d.)/PR—28/369 (7.6%)358/369 (97%)
Total—63/740 (8.5%)717/740 (96.9%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventT12(q8h)/PRT12(b.i.d.)/PRTotal
AnaemiaBlood and lymphatic system disorders14/37113/36927/740
SyncopeNervous system disorders3/3712/3695/740
RashSkin and subcutaneous tissue disorders1/3712/3693/740
VertigoEar and labyrinth disorders0/3712/3692/740
ThrombocytopeniaBlood and lymphatic system disorders2/3710/3692/740
DehydrationMetabolism and nutrition disorders2/3710/3692/740
PancytopeniaBlood and lymphatic system disorders1/3711/3692/740
Urinary tract infectionInfections and infestations1/3711/3692/740
PneumoniaInfections and infestations0/3711/3691/740
AstheniaGeneral disorders1/3711/3692/740
Most frequent other events
Showing 10 of 38
Most frequent other events
EventT12(q8h)/PRT12(b.i.d.)/PRTotal
FatigueGeneral disorders178/371173/369351/740
PruritusSkin and subcutaneous tissue disorders158/371158/369316/740
AnaemiaBlood and lymphatic system disorders148/371155/369303/740
NauseaGastrointestinal disorders143/371129/369272/740
RashSkin and subcutaneous tissue disorders133/371129/369262/740
HeadacheNervous system disorders108/37187/369195/740
PyrexiaGeneral disorders78/37162/369140/740
Influenza like illnessGeneral disorders60/37175/369135/740
AstheniaGeneral disorders72/37165/369137/740
DiarrhoeaGastrointestinal disorders71/37149/369120/740

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)T12(q8h)/PRT12(b.i.d.)/PRTotal
<=18 years303
Between 18 and 65 years351362713
>=65 years17724
Age, Continuous
Age, Continuous(years)T12(q8h)/PRT12(b.i.d.)/PRTotal
Mean48 (18 to 70)47.5 (19 to 70)47.7 (18 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)T12(q8h)/PRT12(b.i.d.)/PRTotal
Female136160296
Male235209444
Region of Enrollment
Region of Enrollment(participants)T12(q8h)/PRT12(b.i.d.)/PRTotal
Europe192179371
North-America126137263
Australia282856
Mexico549
Brazil202141
08

Study locations

102 sites
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • New Haven, Connecticut, United States
  • Bradenton, Florida, United States
  • Jacksonville, Florida, United States
  • Atlanta, Georgia, United States
  • Marietta, Georgia, United States
  • Chicago, Illinois, United States
  • Downers Grove, Illinois, United States
  • New Orleans, Louisiana, United States
  • Lutherville, Maryland, United States
  • Kansas City, Missouri, United States
  • Lebanon, New Hampshire, United States
  • Egg Harbor Twp, New Jersey, United States
  • Santa Fe, New Mexico, United States
  • New York, New York, United States
  • Charlotte, North Carolina, United States
  • Durham, North Carolina, United States
  • Statesville, North Carolina, United States
  • Winston Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Allentown, Pennsylvania, United States
  • Hershey, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • Charleston, South Carolina, United States
  • Columbia, South Carolina, United States
  • Arlington, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Falls Church, Virginia, United States
  • Norfolk, Virginia, United States
  • Seattle, Washington, United States
  • Adelaide, Australia
  • Camperdown, Australia
  • Clayton, Australia
  • Darlinghurst, Australia
  • Fitzroy, Australia
  • Greenslopes, Australia
  • Melbourne, Australia
  • Perth, Australia
  • Graz N/A, Austria
  • Linz, Austria
  • Wien, Austria
  • Antwerpen, Belgium
  • Brussels, Belgium
  • Genk, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Liege, Belgium
  • Campinas, Brazil
  • Salvador, Brazil
  • Santo Andre, Brazil
  • Sao Paulo, Brazil
  • São Paulo, Brazil
  • Clichy, France
  • Creteil, France
  • Grenoble, France
  • Lille, France
  • Lyon, France
  • Paris, France
  • Pessac, France
  • Vandoeuvre Les Nancy, France
  • Villejuif Cedex, France
  • Berlin, Germany
  • Bochum, Germany
  • Essen, Germany
  • Frankfurt, Germany
  • Hamburg, Germany
  • Kiel, Germany
  • Mainz, Germany
  • Regensburg, Germany
  • Dublin 9, Ireland
  • Dublin, Ireland
  • Mex Ctity, Mexico
  • Mexico, Mexico
  • Monterrey, Mexico
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Czeladz, Poland
  • Kielce, Poland
  • Krakow, Poland
  • Warszawa, Poland
  • Barcelona N/A, Spain
  • Barcelona, Spain
  • Madrid, Spain
  • Malaga N/A, Spain
  • Santander N/A, Spain
  • Sevilla N/A, Spain
  • Valencia, Spain
  • Göteborg, Sweden
  • Malmö, Sweden
  • Stockholm, Sweden
  • Birmingham, United Kingdom
  • Edinburgh, United Kingdom
  • Glasgow, United Kingdom

Showing the first 100 of 102 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sarrazin C, Dierynck I, Cloherty G, Ghys A, Janssen K, Luo D, Witek J, Buti M, Picchio G, De Meyer S. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay. J Clin Microbiol. 2015 Apr;53(4):1264-9. doi: 10.1128/JCM.03030-14. Epub 2015 Feb 4. PubMed 25653396 ↗
  • Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, Brown RS Jr, Hezode C, Rizzetto M, Parana R, De Meyer S, De Masi R, Luo D, Bertelsen K, Witek J. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology. 2014 Mar;146(3):744-753.e3. doi: 10.1053/j.gastro.2013.11.047. Epub 2013 Dec 4. PubMed 24316262 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Aug 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2010
First posted
Nov 16, 2010
Start
Dec 2010
Primary completionActual
Aug 2012
CompletionActual
Nov 2012
Results first posted
Jun 4, 2014
Last update
Jun 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01241760
Lead sponsor
Janssen Infectious Diseases BVBA
Responsible party
Sponsor
First posted
Nov 16, 2010
Start date
Dec 2010
Primary completion
Aug 2012
Completion
Nov 2012
Results posted
Jun 4, 2014
Last update
Jun 4, 2014

Study contacts

Janssen Infectious Diseases BVBA Clinical Trial
study director · Janssen Infectious Diseases BVBA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ribavirin · Telaprevir · Peginterferon alfa-2a

Start the discussion